UroGen Pharma (URGN) Non-Current Assets (2016 - 2026)

UroGen Pharma (URGN) has reported Non-Current Assets for 11 consecutive years, with $16.2 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Assets rose 55.41% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 million (up 98.38% YoY) and the FY2025 annual result came in at $14.4 million, up 50.7% from the prior year.
• Non-Current Assets improved to $16.2 million in Q1 2026 per URGN's latest filing, from $14.4 million in the prior quarter.
• Over the last five years, Non-Current Assets for URGN reached as high as $17.0 million in Q1 2023 and fell as low as $2.9 million in Q2 2024.
• A 5-year average of $10.0 million and a median of $9.6 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets slumped 79.46% — and 2025, when it jumped 311.28%.
• Year by year, Non-Current Assets stood at $6.7 million in 2022, then surged by 35.95% to $9.1 million in 2023, then grew by 4.94% to $9.6 million in 2024, then surged by 50.7% to $14.4 million in 2025, then increased by 12.44% to $16.2 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $16.2 million, $14.4 million, and $16.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.